Izenivetmab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | Nerve growth factor (NGF) |
| Clinical data | |
| Trade names | Lenivia |
| Other names | ZTS-00075623 |
| Routes of administration | Subcutaneous |
| ATCvet code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| Chemical and physical data | |
| Formula | C6570H10078N1750O2022S48 |
| Molar mass | 147472.00 g·mol−1 |
Izenivetmab, sold under the brand name Lenivia, is a canine monoclonal antibody medication used for the alleviation of pain associated with osteoarthritis in dogs.
Izenivetmab was authorized for veterinary use in Canada in October 2025, and in the European Union in November 2025.